Cargando…

Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome"

BACKGROUND: The "PTEN hamartoma tumor syndrome" (PHTS) includes a group of syndromes caused by germline mutations within the tumor suppressor gene "phosphatase and tensin homolog deleted on chromosome ten" (PTEN), characterized by multiple polyps in the gastrointestinal tract and...

Descripción completa

Detalles Bibliográficos
Autores principales: Galatola, Martina, Paparo, Lorella, Duraturo, Francesca, Turano, Mimmo, Rossi, Giovanni Battista, Izzo, Paola, De Rosa, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353236/
https://www.ncbi.nlm.nih.gov/pubmed/22520842
http://dx.doi.org/10.1186/1471-2350-13-28
_version_ 1782233018357776384
author Galatola, Martina
Paparo, Lorella
Duraturo, Francesca
Turano, Mimmo
Rossi, Giovanni Battista
Izzo, Paola
De Rosa, Marina
author_facet Galatola, Martina
Paparo, Lorella
Duraturo, Francesca
Turano, Mimmo
Rossi, Giovanni Battista
Izzo, Paola
De Rosa, Marina
author_sort Galatola, Martina
collection PubMed
description BACKGROUND: The "PTEN hamartoma tumor syndrome" (PHTS) includes a group of syndromes caused by germline mutations within the tumor suppressor gene "phosphatase and tensin homolog deleted on chromosome ten" (PTEN), characterized by multiple polyps in the gastrointestinal tract and by a highly increased risk of developing malignant tumours in many tissues. The current work clarifies the molecular basis of PHTS in three unrelated Italian patients, and sheds light on molecular pathway disregulation constitutively associated to PTEN alteration. METHODS: We performed a combination of RT-PCR, PCR, sequencing of the amplified fragments, Real Time PCR and western blot techniques. RESULTS: Our data provide the first evidence of β-catenin accumulation in blood cells of patients with hereditary cancer syndrome caused by germ-line PTEN alteration. In addition, for the first time we show, in all PHTS patients analysed, alterations in the expression of TNFα, its receptors and IL-10. Importantly, the isoform of TNFRI that lacks the DEATH domain (TNFRSF1β) was found to be overexpressed. CONCLUSION: In light of our findings, we suggest that the PTEN pathway disregulation could determine, in non-neoplastic cells of PHTS patients, cell survival and pro-inflammatory stimulation, mediated by the expression of molecules such as β-catenin, TNFα and TNFα receptors, which could predispose these patients to the development of multiple cancers.
format Online
Article
Text
id pubmed-3353236
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33532362012-05-16 Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome" Galatola, Martina Paparo, Lorella Duraturo, Francesca Turano, Mimmo Rossi, Giovanni Battista Izzo, Paola De Rosa, Marina BMC Med Genet Research Article BACKGROUND: The "PTEN hamartoma tumor syndrome" (PHTS) includes a group of syndromes caused by germline mutations within the tumor suppressor gene "phosphatase and tensin homolog deleted on chromosome ten" (PTEN), characterized by multiple polyps in the gastrointestinal tract and by a highly increased risk of developing malignant tumours in many tissues. The current work clarifies the molecular basis of PHTS in three unrelated Italian patients, and sheds light on molecular pathway disregulation constitutively associated to PTEN alteration. METHODS: We performed a combination of RT-PCR, PCR, sequencing of the amplified fragments, Real Time PCR and western blot techniques. RESULTS: Our data provide the first evidence of β-catenin accumulation in blood cells of patients with hereditary cancer syndrome caused by germ-line PTEN alteration. In addition, for the first time we show, in all PHTS patients analysed, alterations in the expression of TNFα, its receptors and IL-10. Importantly, the isoform of TNFRI that lacks the DEATH domain (TNFRSF1β) was found to be overexpressed. CONCLUSION: In light of our findings, we suggest that the PTEN pathway disregulation could determine, in non-neoplastic cells of PHTS patients, cell survival and pro-inflammatory stimulation, mediated by the expression of molecules such as β-catenin, TNFα and TNFα receptors, which could predispose these patients to the development of multiple cancers. BioMed Central 2012-04-20 /pmc/articles/PMC3353236/ /pubmed/22520842 http://dx.doi.org/10.1186/1471-2350-13-28 Text en Copyright ©2012 Galatola et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Galatola, Martina
Paparo, Lorella
Duraturo, Francesca
Turano, Mimmo
Rossi, Giovanni Battista
Izzo, Paola
De Rosa, Marina
Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome"
title Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome"
title_full Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome"
title_fullStr Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome"
title_full_unstemmed Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome"
title_short Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome"
title_sort beta catenin and cytokine pathway dysregulation in patients with manifestations of the "pten hamartoma tumor syndrome"
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353236/
https://www.ncbi.nlm.nih.gov/pubmed/22520842
http://dx.doi.org/10.1186/1471-2350-13-28
work_keys_str_mv AT galatolamartina betacateninandcytokinepathwaydysregulationinpatientswithmanifestationsoftheptenhamartomatumorsyndrome
AT paparolorella betacateninandcytokinepathwaydysregulationinpatientswithmanifestationsoftheptenhamartomatumorsyndrome
AT duraturofrancesca betacateninandcytokinepathwaydysregulationinpatientswithmanifestationsoftheptenhamartomatumorsyndrome
AT turanomimmo betacateninandcytokinepathwaydysregulationinpatientswithmanifestationsoftheptenhamartomatumorsyndrome
AT rossigiovannibattista betacateninandcytokinepathwaydysregulationinpatientswithmanifestationsoftheptenhamartomatumorsyndrome
AT izzopaola betacateninandcytokinepathwaydysregulationinpatientswithmanifestationsoftheptenhamartomatumorsyndrome
AT derosamarina betacateninandcytokinepathwaydysregulationinpatientswithmanifestationsoftheptenhamartomatumorsyndrome